ECM
UTHR icon

Element Capital Management’s United Therapeutics UTHR Stock Holding History

Element Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,772
Closed -$2.7M – 134
2025
Q1 		$2.7M Buy
+8,772
New +$3.01M 0.67% 73
2019
Q2 		– Sell
-5,393
Closed -$633K – 717
2019
Q1 		$633K Sell
5,393
-11,882
-69% -$1.38M 0.02% 439
2018
Q4 		$1.88M Sell
17,275
-5,891
-25% -$683K 0.05% 231
2018
Q3 		$2.96M Buy
23,166
+4,936
+27% +$611K 0.06% 244
2018
Q2 		$2.06M Sell
18,230
-2,837
-13% -$312K 0.06% 148
2018
Q1 		$2.37M Buy
+21,067
New +$2.68M 0.06% 147

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Element Capital Management's UTHR Position: Q2 2025 in Review

Element Capital Management sold out of United Therapeutics (UTHR) in Q2 2025, closing a stake of 8,772 shares — an estimated $2.7M sold.

Element Capital Management first reported a position in UTHR in Q1 2018 and held it in 6 quarters. The position peaked at $2.96M in Q3 2018. 670 funds tracked by Wall St. Rank hold UTHR as of Q2 2025.

  • Element Capital Management reported no remaining United Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Element Capital Management sold 8,772 United Therapeutics shares in Q2 2025, an estimated $2.7M.
  • Element Capital Management first reported a position in United Therapeutics in Q1 2018 and held it in 6 quarters.
  • Element Capital Management's United Therapeutics position peaked at $2.96M in Q3 2018.
  • 670 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2025.

Based on Element Capital Management's 13F filing for Q2 2025, filed 11 Aug 2025.